Stockscreener 앱 받기
0.34
0.00%
0.00
시간 외 거래:
.33
-0.01
-2.94%
전일 마감가:
$0.34
열려 있는:
$0.33
하루 거래량:
1.32M
Relative Volume:
0.48
시가총액:
$2.27M
수익:
$12.99M
순이익/손실:
$-23.72M
주가수익비율:
-0.0035
EPS:
-97.2514
순현금흐름:
$-23.28M
1주 성능:
-17.07%
1개월 성능:
-66.34%
6개월 성능:
-96.22%
1년 성능:
-98.87%
1일 변동 폭
$0.3282
$0.3455
1주일 범위
$0.3282
$0.4199
52주 변동 폭
$0.3282
$32.93
Aptevo Therapeutics Inc Stock (APVO) Company Profile
명칭
Aptevo Therapeutics Inc
전화
206-838-0500
주소
2401 4TH AVE., SEATTLE, WA
APVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
0.34 | 2.27M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-11-05 | 개시 | Ladenburg Thalmann | Buy |
| 2017-10-05 | 재개 | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc 주식(APVO)의 최신 뉴스
Aptevo Therapeutics (APVO) Expected to Announce Earnings on Wednesday - Defense World
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Therapeutics Provides Program Update for Bispecific APVO7 - GuruFocus
Aptevo Therapeutics Says In Preclinical Studies APVO711 Demonstrates Dual Anti-Cancer Functionality - marketscreener.com
Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy wit - GuruFocus
Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy with APVO711 Update | APVO Stock News - GuruFocus
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation | APVO Stock News - GuruFocus
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation - ACCESS Newswire
Aptevo Therapeutics announces common stock offering - Investing.com Australia
APVO’s latest rating updates from top analysts. - knoxdaily.com
Strategic Moves Drive Stock Gains For OSR, Lianhe Sowell, And Aptevo - Finimize
Aptevo Therapeutics announces common stock offering By Investing.com - Investing.com Canada
Closing Bell Recap: Aptevo Therapeutics Inc (APVO) Ends at 0.61, Reflecting a -9.31 Downturn - DWinneX
Aptevo Therapeutics announces at-the-market offering - Investing.com Australia
APVO stock plunges to 52-week low, touches $0.59 - Investing.com
APVO stock plunges to 52-week low, touches $0.59 By Investing.com - Investing.com UK
Aptevo Therapeutics announces at-the-market offering By Investing.com - Investing.com India
SEC Form 424B4 filed by Aptevo Therapeutics Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering - ACCESS Newswire
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire
Applied Materials Q2 Earnings: Tech Giant's Financial Results Coming May 15 - Stock Titan
A look into Aptevo Therapeutics Inc (APVO)’s deeper side - Sete News
Aptevo Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com
Evogene (EVGN) Sees Dramatic Surge in Investor Interest Amid Strategic Moves | APVO Stock News - GuruFocus
Market Momentum: Aptevo Therapeutics Inc (APVO) Registers a 9.08 Increase, Closing at 0.69 - DWinneX
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | APVO Stock News - GuruFocus
Aptevo Therapeutics Raises Fresh Capital: $2M Direct Offering to Advance Cancer Drug Pipeline - Stock Titan
Aptevo Therapeutics Inc (APVO) Shares Are Down -85.25% YTD - Marketing Sentinel
Aptevo Therapeutics announces $2 million stock offering By Investing.com - Investing.com India
Aptevo Therapeutics $2.0 Million Registered Direct Offering Pric - GuruFocus
Aptevo Therapeutics (APVO) Secures $2M Through Registered Direct Offering | APVO Stock News - GuruFocus
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | APVO Stock News - GuruFocus
Aptevo Therapeutics announces $2 million stock offering - Investing.com
Aptevo Therapeutics Raises Fresh Capital: $2M Boost for Revolutionary Cancer Treatment Development - Stock Titan
Aptevo Therapeutics Inc (APVO) Stock: Navigating a Year of Volatility - investchronicle.com
How does APVO’s price to cash per share ratio compare in the market? - uspostnews.com
Aptevo Therapeutics (APVO) Completes $2.1 Million Stock Offering - GuruFocus
Why Netflix Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Now Is A Good Time To Buy Aptevo Therapeutics Inc (NASDAQ: APVO) - Marketing Sentinel
APVO stock plunges to 52-week low, touches $0.94 By Investing.com - Investing.com South Africa
APVO stock plunges to 52-week low, touches $0.94 - Investing.com Australia
Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 - ACCESS Newswire
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High - Asianet Newsable
Aptevo Therapeutics Inc (APVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):